Assessment of response to therapy in advanced breast cancer.
Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. · 1977
Read Assessment of response to therapy in advanced breast cancer. by Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. (1977) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2025288.txt.
Introduction
Hayward and co-authors proposed in 1977 a shared system for judging treatment response in advanced breast cancer. The project came from the International Union Against Cancer, known as the UICC. Different centres were using different evaluation methods, making published results hard to compare. A single uniform system promised fair comparison across trials. Breast cancer was chosen first because agreement seemed within reach.
A draft document was circulated widely to workers in the field for comment. It was then revised before final publication. The guidelines serve trials that assess objective response in locally advanced or spreading breast cancer. Subjective response, how a patient feels, is not covered. Eligibility requires tissue proof of breast cancer available for review. The British Breast Group accepted the system, replacing its earlier method.
Catalog record
| CREATOR | Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. |
|---|---|
| YEAR | 1977 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Assessment of response to therapy in advanced breast cancer. By J. L. Hayward, P. P. Carbone, J. C. Heusen, S. Kumaoka, A. Segaloff, R. D. Rubens Published in: British Journal of Cancer DOI: 10.1038/bjc.1977.42 ABSTRACT A system is proposed by the UICC for assessing response to treatment of advanced breast cancers. Br. J. Cancer (1977) 35, 292. ASSESSMENT OF RESPONSE TO THERAPY IN ADVANCED BREAST CANCER A PROJECT OF THE PROGAMME ON CLINICAL ONCOLOGY OF THE INTERNATIONAL UNION AGAINST CANCER, GENEVA, SWITZERLAND MEMBERS OF THE PROJECT TEAM: J. L. HAYWARD (CHAIRMAN) AND R. D. RUBENS (SECRETARY) Imperial Cancer Research Fund, Breast Cancer Unit, Guy's Hospital, London P. P. CARBONE Division of Clinical Oncology, Wisconsin Cancer Clinical Centre, University Hospital, Madison, U.S.A. J-C HEUSON Institut Jules Bordet, Centre des Tumeurs de L'Universite Libre de Bruxelles, Belgium S. KUMAOKA National Cancer Centre Hospital, Tokyo, Japan A. SEGALOFF Richard W. Freeman Research Institute, Alton Ochsner Medical Foundation, New Orleans, U.S.A. Received 22 September 1976 Accepted 25 October 1976 Summary.-A system is proposed by the UICC for assessing response to treatment of advanced breast cancers. IN 1975, a project was initiated by the Programme on Clinical Oncology of the UICC to formulate a system for the evaluation of response to treatment of advanced cancer. It was considered that a single uniform system, used inter- nationally, would be invaluable for the accurate comparison of published results from different centres. Advanced breast cancer was selected as the first tumour for consideration, because a number of dif- ferent evaluation methods was already in use (Hayward, 1966; British Breast Group, 1974; Segaloff, 1966; Eastern Co-operative Oncology Group, unpub.; Rozeneweig and Heuson, 1975; Breast Cancer Group in Japan, 1973), and it was felt that agree- ment on a common system might readily be achieved. A preliminary document describing such a system was prepared, and was then circulated to many workers in the field for comment, after which it was revised accordingly. The final document is now presented. It is hoped that this system will be widely adopted and that it may eventually be used as a model for the assessment of therapy of other tumours. It has been accepted by the British Breast Group and replaces its previously pub- lished assessment method (British Breast Group, 1974). 1. Aim These guidelines are intended for use in designing clinical trials to assess the objective response of locally advanced or metastatic mammary cancer to treatment; subjective response to treatment is not considered. 2. Criteria of eligibility 2.1. Histological evidence of breast cancer available for review. RESPONSE TO THERAPY IN ADVANCED BREAST CANCER 2.2. Objective evidence of progression of disease, i.e. new lesions appear or existing lesions become larger. 2.3. Bulk of clinical disease must be evaluable by either direct measurement or photography and/or radiography. 3. Exclusions 3.1. It is recognized that many factors may affect a patients ability to tolerate specific therapy. The following should, therefore, be considered in the selection of patients for study: 3.1. 1. Debility. 3.1.2. Associated medical conditions. 3.1. 3. Previous antitumour therapy (especially chemotherapy and radio- therapy). 3.1.4. Other previous or concurrent treat- ment. 3.2. The following are factors which seriously compromise the evaluation of results and lead to the exclusion of patients from a study of systemic therapy: 3.2.1. Previous or current malignancies at other sites, with the exception of cone-biopsied in situ carcinoma of the cervix uteri and adequately treated basal or squamous cell carcinoma of the skin. 3.2.2. Patients in whom one of the fol- lowing is the sole manifestation of disease: lymphoedema hilar enlargement pleural effusion ascites metastases in the central nervous system marrow suppression osteoblastic skeletal lesions. 3. 2. 3. Previous systemic antitumour treatment with the agent(s) under study. 3.2.4. In order to avoid confusion with a withdrawal response or a delayed re- sponse to treatment, it is suggested that patients within 4 weeks of endocrine ablation or cessation of additive hor- mone therapy be excluded. In the case of long-acting hormones or depot pre- parations, this period may have to be increased. When previous chemo- therapy or radiotherapy has been used, the toxic manifestations of these treat- ments, which affect subsequent specific therapy, must have resolved. After 4 weeks the patient can be included only if there is evidence of progressive disease. 4. Baseline studies 4.1. History.-A standard history should be obtained in all cases, with special attention to: 4.1.1. Stage of primary disease at the time of initial presentation, expressed if possible in the TNM Classification (International Union Against Cancer, 1974), and its histology and pathological extent. 4.1.2. Recording of race, dates of birth, diagnosis of breast cancer and last menstrual period. 4.1.3. The extent and date of treatment of the primary tumour and the time of first recurrence should be noted. The date of first recurrence should be given as the time of documentation of the first sign, not symptom, confirmed subsequently to be a recurrence. 4.1.4. Dates, agents and the recorded result of previous treatment of recurrent breast cancer. 4.1.5. Concurrent diseases. 4.1.6. Other past and present treatment. 4.2. Performance.-An estimation of per- formance may be an important part of evaluation. The Karnofsky system (Karnofsky and Burchenal, 1948) would be appropriate, or the following 5-grade system could be used: GRADE PERFORMANCE 0 Fully active, able to carry on all usual activities without restriction and without the aid of analgesia. 1 Restricted in strenuous acti- vity but ambulatory and able to carry out light work or 293 I J. L. HAYWARD ET AL. pursue a sedentary occupation. Also patients who are fully active, as in Grade 0, but only with the aid of analgesics. 2 Ambulatory and capable of all self-care but unable to work. Up and about more than 50 % of waking hours. 3 Capable of only limited self- care, confined to bed or chair more than 50 % of waking hours. 4 Completely disabled, unable to carry out any self-care and confined totally to bed or chair. 4.3. Physical examination.-Before start- ing new treatment, a full physical examination including measurement of height and weight should be done on all patients. Special attention should be directed to tissues or organs where toxic manifestations of treatment might be expected to develop. Superficial and palpable lesions should be measured directly (in cm) along 2 axes-one being the longest, and the other, the longest perpendicular to it. Callipers may improve the accuracy of the measurements. 4. 4. Photographs.-Colour photographs of all visible lesions, together with identifi- cations, date and cm rule should be taken. 4.5. Radiographs.-The following sites should be radiographed for baseline information with standardized exposures if possible: chest skull total spine pelvis femora and an isotopic bone scan should be done. 4.6. Laboratory studies.-Because thera- peutic agents and/or cancer may affect normal function, appropriate investi- gations should be carried out to evaluate cardiac, pulmonary, metabolic, hepatic, renal, endocrine and marrow status before treatment is started. 4. 7. Additional studies.-When appropri- ate and feasible, the following might be helpful: --radio-isotope scans of brain, bone and liver computerized axial transverse (CAT) scans mammography bone marrow biopsy - laparoscopy - thoracoscopy - hormone receptor assays - potential markers of disease, e.g. CEA, HCG, dimethyl-guanosine - ultra-sonography - immunological evaluation - hydroxyproline